1-8 of 8
Ronald de Wit
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2050–2060.
https://doi.org/10.1158/1078-0432.CCR-21-3089
Published: 13 May 2022
View article titled, Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Open the PDF for Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials in another window
Includes: Supplementary data
Journal Articles

Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8+ T cells

Maud Rijnders, Hayri E. Balcioglu, Debbie G.J. Robbrecht, Astrid A.M. Oostvogels, Rebecca Wijers, Maureen J.B. Aarts, Paul Hamberg, Geert J.L.H. van Leenders, J. Alberto Nakauma-González, Jens Voortman, Hans M. Westgeest, Joost L. Boormans, Ronald de Wit, Martijn P. Lolkema, Astrid A.M. van der Veldt, Reno Debets
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 215–226.
https://doi.org/10.1158/1078-0432.CCR-20-3319
Published: 05 January 2022
View article titled, Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells
Open the PDF for Anti–PD-1 Efficacy in Patients with Metastatic Urothelial Cancer Associates with Intratumoral Juxtaposition of T Helper-Type 1 and CD8<sup>+</sup> T cells in another window
Includes: Supplementary data
Journal Articles

Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study

Edwin M. Posadas, Kim N. Chi, Ronald de Wit, Maja J.A. de Jonge, Gerhardt Attard, Terence W. Friedlander, Margaret K. Yu, Peter Hellemans, Caly Chien, Charlene Abrams, Juhui J. Jiao, Fred Saad
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3517–3524.
https://doi.org/10.1158/1078-0432.CCR-19-3402
Published: 15 July 2020
View article titled, Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study
Open the PDF for Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study in another window
Includes: Supplementary data
Journal Articles

Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug–Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients

Bodine P.S. Belderbos, Sander Bins, Roelof W.F. van Leeuwen, Esther Oomen-de Hoop, Nelly van der Meer, Peter de Bruijn, Paul Hamberg, Esther N.M. Overkleeft, Wendy M. van der Deure, Martijn P. Lolkema, Ronald de Wit, Ron H.J. Mathijssen
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (3): 541–546.
https://doi.org/10.1158/1078-0432.CCR-17-2336
Published: 31 January 2018
View article titled, Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug–Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients
Open the PDF for Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug–Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients in another window
Journal Articles

Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study

Annemieke J.M. Nieuweboer, Anne-Joy M. de Graan, Paul Hamberg, Sander Bins, Robert J. van Soest, Robbert J. van Alphen, Andries M. Bergman, Aart Beeker, Henk van Halteren, Albert J. ten Tije, Hanneke Zuetenhorst, Nelly van der Meer, Dana Chitu, Ronald de Wit, Ron H.J. Mathijssen
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (7): 1679–1683.
https://doi.org/10.1158/1078-0432.CCR-16-2110
Published: 02 April 2017
View article titled, Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study
Open the PDF for Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study in another window
Includes: Supplementary data
Journal Articles

Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer

Andrew J. Armstrong, Elizabeth Garrett-Mayer, Ronald de Wit, Ian Tannock, Mario Eisenberger
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 203–211.
https://doi.org/10.1158/1078-0432.CCR-09-2514
Published: 04 January 2010
View article titled, Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Open the PDF for Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

Dominik R. Berthold, Gregory R. Pond, Martin Roessner, Ronald de Wit, Mario Eisenberger, and Ian F. Tannock, on behalf of the TAX-327 investigators
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2763–2767.
https://doi.org/10.1158/1078-0432.CCR-07-0944
Published: 01 May 2008
View article titled, Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study
Open the PDF for Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study in another window
Journal Articles

A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis

Andrew J. Armstrong, Elizabeth S. Garrett-Mayer, Yi-Chun Ou Yang, Ronald de Wit, Ian F. Tannock, Mario Eisenberger
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (21): 6396–6403.
https://doi.org/10.1158/1078-0432.CCR-07-1036
Published: 01 November 2007
View article titled, A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis
Open the PDF for A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis in another window
Includes: Supplementary data